Comparative Pharmacology
Head-to-head clinical analysis: HALDOL versus QUIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALDOL versus QUIDE.
HALDOL vs QUIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Haloperidol is a typical antipsychotic that blocks dopamine D2 receptors in the central nervous system, particularly in the mesolimbic and mesocortical pathways, reducing positive symptoms of schizophrenia. It also has moderate affinity for sigma receptors and weak affinity for serotonin 5-HT2, alpha-adrenergic, and histamine H1 receptors.
Quetiapine acts as an antagonist at multiple neurotransmitter receptors in the brain, including serotonin 5-HT2A, dopamine D2, histamine H1, and adrenergic α1 receptors. It also has partial agonist activity at serotonin 5-HT1A receptors. This atypical antipsychotic action is mediated primarily through 5-HT2A and D2 antagonism.
Initial: 1-5 mg PO/IM twice daily; titrate up to 5-10 mg/day. Acute agitation: 5-10 mg IM every 1-8 hours. Maintenance: 5-10 mg/day PO/IM. Maximum: 100 mg/day.
5 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 21 hours (range 12–37 hours). Extended half-life in chronic administration supports once-daily dosing; dose adjustments required in hepatic impairment.
2-4 hours (prolonged in renal impairment, requiring dose adjustment)
Renal (approximately 40%, with 1% unchanged; remainder as metabolites) and fecal (approximately 60%, primarily via bile).
Primarily renal (80% as unchanged drug); minor fecal (20%)
Category C
Category C
Antipsychotic
Antipsychotic